Takeda Receives US Clearance for $62-Billion Acquisition of Shire

Article

The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.

On July 10, 2018, Takeda Pharmaceutical announced that it received clearance from the United States Federal Trade Commission for its proposed $62-billion acquisition of Shire.

The acquisition, announced in May 2018, remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies. Under the terms of the agreement, each Shire shareholder will receive $30.33 in cash for each Shire share and Takeda shares. The boards of directors of both companies have approved the transaction, which is expected to close in the first half of 2019. Upon closing, Takeda shareholders will own approximately 50% of the combined group.

Shire is headquartered in Dublin, Ireland, and achieved more than $15 billion in 2017 revenues

According to Takeda, the acquisition will strengthen its core therapeutic areas of oncology, gastrointestinal, and neuroscience and boosts Takeda’s position in specialized medicines through the addition of Shire’s global rare-disease franchise.

Source: Takeda Pharmaceutical

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
David Fairen-Jimenez
William K. Oh, MD
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.